ScreenerHero

TNGX Tango Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · tangotx.com
21.83USD-0.32%Mkt Cap: 3.68B $P/E: —

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative prot…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.68B USD
Enterprise Value2.71B USD
Revenue (TTM)53.81M USD
Gross Profit-79.84M USD
Net Income (TTM)-101.59M USD
Revenue/Share0.40 USD
Last Price21.83 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees137
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.00
PEG—
EV/EBITDA-20.16
EV/Revenue50.37
P/S68.62
P/B3.60
EPS (TTM)-0.81
EPS (Forward)-1.69
52W Range
6.69055% of range34.39
52W High34.39 USD
52W Low6.690 USD
Profitability
Gross Margin-148.37%
Oper. Margin-253.38%
EBITDA Margin-249.81%
Profit Margin-162.85%
ROE-29.35%
ROA-25.48%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-138.89M USD
CapEx (TTM)1.05M USD
FCF Margin-133.57%
FCF Yield-1.95%
Net Debt-982.00M USD
Net Debt/EBITDA7.31
Balance Sheet
Debt/Equity0.10
Current Ratio50.82
Quick Ratio49.95
Book Value/Sh6.08 USD
Cash/Share6.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)45.18 USD
Upside (mean)+107.0%
Target Range24.00 USD – 69.00 USD
24.00+107.0% to mean69.00
# Analysts11
Ownership
Shares Out.168.61M
Float120.67M
Insiders1.19%
Institutions128.44%
Short Interest
Short Ratio18.6d
Short % Float25.11%
Short % Out.24.83%
Shares Short41.87M
Short (prev mo.)43.19M
Technical
SMA 5024.86 (-12.2%)
SMA 20021.02 (+3.8%)
Beta1.17
S&P 52W Chg16.45%
Avg Vol (30d)2.98M
Avg Vol (10d)3.66M
Technical Indicators
RSI (14)38.7
MACD-0.6270
MACD Signal-0.4883
MACD Hist.-0.1387
BB Upper25.95 USD
BB Middle23.71 USD
BB Lower21.48 USD
BB Width18.86%
ATR (14)1.612 USD
Vol Ratio (20d)1.01x